Clinical trial
A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Glepaglutide in Patients With Short Bowel Syndrome (SBS)
NCT03690206 is registered in ClinicalTrials.gov with Zealand Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Glepaglutide in Patients With Short Bowel Syndrome (SBS)
- Lead sponsor
- Zealand Pharma
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 4, 2018
- Completion date
- July 26, 2022
- Enrollment
- 106 (actual)
- Sites
- 29
Conditions
As the registry lists them; a condition with its own page is linked.